Abstract
Cas12f is a hypercompact type V, Cas12 family member. Previously, we reported a set of engineered guide RNAs supporting high indel efficiency for Cas12f1 in human cells. Here we suggest a new technology whereby the engineered guide RNAs also manifest high-efficiency programmable endonuclease activity for a Cas12f variant. We have termed this technology TaRGET (Tiny nuclease RNA-based Genome Editing Technology). Having this feature in mind, we established TaRGET-based adenine base editors (ABEs). A Tad–Tad mutant (V106W, D108Q) dimer fused to the C terminus of dCas12f (D354A) showed the highest levels of A-to-G conversion. The limited targetable sites for TaRGET-ABE were expanded with engineered variants of Cas12f or optimized deaminases. Delivery of TaRGET-ABE also ensured potent A-to-G conversion rates in mammalian genomes. Collectively, the TaRGET-ABE will contribute to improving precise genome-editing tools that can be delivered by adeno-associated viruses, thereby harnessing the development of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Data that support the findings of this study are available within the Article and its Supplementary Information. Deep-sequencing data for large-scale validation and RNA-seq data were deposited at the NCBI Sequence Read Archive database (http://www.ncbi.nlm.nih.gov/sra) under accession number PRJNA823884. All other data that support the findings of the present study and plasmid vectors are available from the corresponding author upon request. Source data are provided with this paper.
Code availability
Reditools is available at https://github.com/BioinfoUNIBA/REDItools2. MAUND is available at https://github.com/ibs-cge/maund.
Change history
16 February 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41589-023-01258-w
References
Bamshad, M. J. et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12, 745–755 (2011).
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
Kurt, I. C. et al. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat. Biotechnol. 39, 41–46 (2021).
Porto, E. M. et al. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839–859 (2020).
Naeem, M., Majeed, S., Hoque, M. Z. & Ahmad, I. Latest developed strategies to minimize the off-target effects in CRISPR–Cas-mediated genome editing. Cells 9, 1608 (2020).
Molla, K. A. & Yang, Y. CRISPR/Cas-mediated base editing: technical considerations and practical applications. Trends Biotechnol. 37, 1121–1142 (2019).
Stevanovic, M., Piotter, E., McClements, M. E. & MacLaren, R. E. CRISPR systems suitable for single AAV vector delivery. Curr. Gene Ther. 22, 1–14 (2022).
Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).
Li, C. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 255–272 (2020).
Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80–86 (2010).
Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97–110 (2020).
Chand, D. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J. Hepatol. 74, 560–566 (2021).
Kim, D. Y. et al. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus. Nat. Biotechnol. 40, 94–102 (2021).
Xu, X. et al. Engineered miniature CRISPR–Cas system for mammalian genome regulation and editing. Mol. Cell 81, 4333–4345 (2021).
Wu, Z. et al. Programmed genome editing by a miniature CRISPR–Cas12f nuclease. Nat. Chem. Biol. 17, 1132–1138 (2021).
Altae-Tran, H. et al. The widespread IS200/IS605 transposon family encodes diverse programmable RNA-guided endonucleases. Science 374, 57–65 (2021).
Karvelis, T. et al. Transposon-associated TnpB is a programmable RNA-guided DNA endonuclease. Nature 599, 692–696 (2021).
Shmakov, S. et al. Diversity and evolution of class 2 CRISPR–Cas systems. Nat. Rev. Microbiol. 15, 169–182 (2017).
Takeda, S. N. et al. Structure of the miniature type V-F CRISPR–Cas effector enzyme. Mol. Cell 81, 558–570 (2021).
Xiao, R., Li, Z., Wang, S., Han, R. & Chang, L. Structural basis for substrate recognition and cleavage by the dimerization-dependent CRISPR–Cas12f nuclease. Nucleic Acids Res. 49, 4120–4128 (2021).
Molla, K. A. et al. Precise plant genome editing using base editors and prime editors. Nat. Plants 7, 1166–1187 (2021).
Rees, H. A., Wilson, C., Dorman, J. L. & Liu, D. R. Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci. Adv. 8, eaax5717 (2019).
Jeong, Y. K. et al. Adenine base editor engineering reduces editing of bystander cytosines. Nat. Biotechnol. 39, 1426–1433 (2021).
Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883–891 (2020).
Yan, D. et al. High-efficiency and multiplex adenine base editing in plants using new TadA variants. Mol. Plant 14, 722–731 (2021).
Harrington, L. B. et al. Programmed DNA destruction by miniature CRISPR–Cas14 enzymes. Science 362, 839 (2018).
Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620–628 (2020).
Yu, Y. et al. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat. Commun. 11, 2052 (2020).
Nguyen Tran, M. T. et al. Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing. Nat. Commun. 11, 4871 (2020).
Sharma, B., Singh, V. J. & Chawla, P. A. Epidermal growth factor receptor inhibitors as potential anticancer agents: an update of recent progress. Bioorg. Chem. 116, 105393 (2021).
Huang, S. et al. Developing ABEmax-NG with precise targeting and expanded editing scope to model pathogenic splice site mutations in vivo. iScience 15, 640–648 (2019).
Yuan, J. et al. Genetic modulation of RNA splicing with a CRISPR-guided cytidine deaminase. Mol. Cell 72, 380–394 (2018).
Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 463–502 (2021).
Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).
Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).
Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014).
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).
Jung, Y. & Han, D. BWA-MEME: BWA-MEM emulated with a machine learning approach. Bioinformatics 38, 2404–2413 (2022).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10 (2011).
Verdera, H. C., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723–746 (2020).
Acknowledgements
This work was supported by a grant through the KRIBB Research Initiative Program (KGM5382221 to Y.L., D.J., K.-H.P, H.J.C, J.M.L, J.-H.K and Y.-S.K.), the National Research Foundation of Korea (INNOPOLIS) grant (2021-DD-RD-0178-01 to D.Y.K., Y.C., S.P. and Y.-S.K.), and the National Research Foundation of Korea grant (2022R1C1C1013085 to D.Y.K and S.K.) funded by the Ministry of Science and ICT, the ‘Alchemist Project’ funded by the Ministry of Trade, Industry and Energy (20012445 to D.Y.K. and Y.-S.K.), and Cooperative Research Program for Agriculture Science and Technology Development (PJ0165422022 to D.Y.K., Y.C., S.P. and Y.-S.K.) funded by Rural Development Administration.
Author information
Authors and Affiliations
Contributions
Y.-S.K. conceived the study and designed the experiments. D.Y.K. and Y.C. performed overall experiments. D.J and Y.L. constructed the PAM library vectors and PAM variants of CWCas12f. H.J.C. and J.M.L performed base-editing assays in cells. S.P. and S.K. derived PAM-mutant HEK293T cells. K.-H.P performed the structural analysis for CWCas12f engineering. J.-H.K. and Y.-S.K. interpreted data. Y.-S.K. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
D.Y.K., Y.C. and Y.-S.K. have filed patent applications on the TaRGET-ABE and PAM variants of CWCas12f through GenKOre. Y.-S.K. and D.Y.K. are co-founders of GenKOre. The remaining authors declare no other competing interests.
Peer review
Peer review information
Nature Chemical Biology thanks Sangsu Bae, Rahul Kohli and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 Construction of catalytically inactive CWCas12f (dCWCas12f) and confirmation of indel-null activity in HEK293T cells.
a. An agarose gel image showing cleavage pattern of plasmid vector by wild-type or several catalytically dead mutants of CWCas12f. Plasmid vectors were constructed to harbor protospacer and PAM sequence for sgRNA. Five microgram of plasmid vectors were incubated with 1 microgram of gRNA and 2 microgram of CWCas12f or dCWCas12f at 37 °C for 1 h. The cleaved vector samples were resolved on a 0.8% agarose gel. M denotes molecular ladders. The image corresponds to a representative experiment for three independent experiments. b. Indel efficiencies of CWCas12f or dead mutants of CWCas12f at an NLRC4 locus (5’-TTTAGAGGGAGACACAAGTTGATA-3’) in HEK293T cells. n = 3 independent experiments.
Extended Data Fig. 2 Dimerization of CWCas12f in the presence of single-stranded guide RNA.
a. An SDS-PAGE gel image for purified CWCas12f in elution fractions. The gel image corresponds to a representative experiment for six independent experiments. b. Size-exclusion chromatography profiles of CWCas12f proteins in the presence or absence of sgRNA. CWCas12f proteins were incubated with gRNA and the RNP complex was resolved on a Superdex 200 column. The molecular mass was estimated from a standard curve derived from the mobility of molecular ladder proteins.
Extended Data Fig. 3 Identification of the base-editing window of TaRGET-ABE-C2 system.
The substitution profile of TaRGET-ABE-C2 was explored for five endogenous sites in HEK293T cells to define a base editing window. The endogenous sites were selected from the validated sites showing substantial A-to-G conversion activities and also carrying multiple adenine sequences in the PAM-proximal region. The TaRGET-ABE system elicits A-to-G conversions in the range of positions 2–6, but most predominantly at the positions 3-4. The intensity of colors is not proportional to the editing efficiency, but highlights the qualitatively high efficiency positions.
Extended Data Fig. 4 Head-to-head comparison of TaRGET-based adenine base editors and Un1Cas12f1-based ABEMINI.
The efficiency of TaRGET-ABEs was compared with that of ABEMINI at five endogenous loci in HEK293T cells. Specifically, TaRGET-ABE-C2 was compared with ABEMINI to rule out the contribution of Tad engineering to the editing efficiency. The results show significant difference in A-to-G conversion activities in the base-editing window between TaRGET-ABE-C2 and ABEMINI, indicating CWCas12f as a preferred nuclease for hypercompact adenine base editors. The intensity of colors represents of the conversion efficiency. The values represent the means of three independent experiments.
Supplementary information
Supplementary information
Supplementary Figures 1–4 and Supplementary Tables 1–4.
Source data
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 5
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Extended Data Fig. 2
Unprocessed gel image.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kim, D.Y., Chung, Y., Lee, Y. et al. Hypercompact adenine base editors based on a Cas12f variant guided by engineered RNA. Nat Chem Biol 18, 1005–1013 (2022). https://doi.org/10.1038/s41589-022-01077-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-01077-5
This article is cited by
-
Engineered IscB–ωRNA system with expanded target range for base editing
Nature Chemical Biology (2024)
-
Engineering a transposon-associated TnpB-ωRNA system for efficient gene editing and phenotypic correction of a tyrosinaemia mouse model
Nature Communications (2024)
-
Engineering miniature IscB nickase for robust base editing with broad targeting range
Nature Chemical Biology (2024)
-
Epigenome editing technologies for discovery and medicine
Nature Biotechnology (2024)
-
Next-generation CRISPR technology for genome, epigenome and mitochondrial editing
Transgenic Research (2024)